Brief: Paratek Pharmaceuticals Announces Full-Year 2021 Revenue Of $130.2 Million
14/03/2022 11:40
March 14 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 REVENUE
OF
$130.2 MILLION
* SEES FY REVENUE $155 MILLION TO $170 MILLION
* Q4 REVENUE $31.8 MILLION
* PARATEK - SEES EXISTING CASH & CASH EQUIVALENTS AS OF DEC
31,
2021, PROVIDES FOR CASH RUNWAY THROUGH END OF 2023 WITH PATHWAY
TO CASH FLOW BREAK-EVEN
* Q4 LOSS PER SHARE $0.64
* Q4 EARNINGS PER SHARE VIEW $-0.41 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX9DbYbZ
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million